Porter B, Maulik D, Babbar S, et al. - This study was sought to evaluate the hypotheses that soluble placental expression of neuropilin‐1 (sNRP1) would be detectable in maternal circulation, and its concentration would be upregulated in fetal growth restriction (FGR) pregnancies compared to those with normal fetal growth, and its upregulation would correlate with the severity of the disease process as assessed by umbilical artery (UA) Doppler. Between 1/2015 and 5/2017, researchers performed a prospective case‐control pilot study involving 40 pregnancies (control 20, study 20) between 24 0/7 and 40 0/7weeks’ gestation followed in an academic perinatal center. Standard protocols were applied to conduct fetal ultrasound biometry and UA Doppler. A commercially available ELISA was applied to conduct plasma sNRP1 measurements. The findings revealed a significant decrease in maternal plasma soluble NRP1 concentrations in growth-restricted pregnancies with fetoplacental circulatory compromise. The outcomes of this study imply a possible role of sNRP1 in modulating fetal growth, and its potential as a biomarker for fetal growth restriction.